Yulin Zhang

Dr. Yulin Zhang


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2021 in Oncogene
Verified
Journal Article
Open access
PDF file
YZYulin Zhang
Yulin Zhang
YKYang Kong
Yang Kong
YMYuan Ma
Yuan Ma
SNShilei Ni
Shilei Ni
TWTobias Wikerholmen
Tobias Wikerholmen
XLXin-gang Li
Xin-gang Li
Dysregulated iron metabolism is a hallmark of many cancers, including glioblastoma (GBM). However, its role in tumor progression remains unclear. Herein, we identified coatomer protein complex subunit zeta 1 (COPZ1) as a therapeutic target candidate which significantly dysregulated iron metabolism in GBM cells. Overexpression of COPZ1 was associated with increasing tumor grade and poor prognosis in glioma patients based on analysis of expression data from the publicly available database The Cancer Genome Atlas (P < 0.001). Protein levels of COPZ1 were significantly increased in GBM compared to non-neoplastic brain tissue samples in immunohistochemistry and western blot analysis. SiRNA knockdown of COPZ1 suppressed proliferation of U87MG, U251 and P3#GBM in vitro. Stable expression of a COPZ1 shRNA construct in U87MG inhibited tumor growth in vivo by ~60% relative to controls at day 21 after implantation (P < 0.001). Kaplan–Meier analysis of the survival data demonstrated that the overall survival of tumor bearing animals increased from 20.8 days (control) to 27.8 days (knockdown, P < 0.05). COPZ1 knockdown also led to the increase in nuclear receptor coactivator 4 (NCOA4), resulting in the degradation of ferritin, and a subsequent increase in the intracellular levels of ferrous iron and ultimately ferroptosis. These data demonstrate that COPZ1 is a critical mediator in iron metabolism. The COPZ1/NCOA4/FTH1 axis is therefore a novel therapeutic target for the treatment of human GBM.

27 August 2023 in Advanced Functional Materials
Verified
Journal Article
Closed access
HGHuimin Geng
Huimin Geng
XZXiaoyue Zheng
Xiaoyue Zheng
YZYulin Zhang
Yulin Zhang
XCXiaomiao Cui
Xiaomiao Cui
ZLZhiwei Li
Zhiwei Li
SNShilei Ni
Shilei Ni

14 June 2024 in Science Advances
Verified
Journal Article
Open access
YWYan Wang
Yan Wang
JZJing Zhang
Jing Zhang
YLYing Liu
Ying Liu
XYXiao Yue
Xiao Yue
KHKun Han
Kun Han
XJXinyi Jiang
Xinyi Jiang
The stemness loss–associated dysregeneration of impaired alveolar type 2 epithelial (AT2) cells abolishes the reversible therapy of idiopathic pulmonary fibrosis (IPF). We here report an inhalable mucus-penetrating lipid nanoparticle (LNP) for codelivering dual mRNAs, promoting realveolarization via restoring AT2 stemness for IPF treatment. Inhalable LNPs were first formulated with dipalmitoylphosphatidylcholine and our in-house–made ionizable lipids for high-efficiency pulmonary mucus penetration and codelivery of dual messenger RNAs (mRNAs), encoding cytochrome b5 reductase 3 and bone morphogenetic protein 4, respectively. After being inhaled in a bleomycin model, LNPs reverses the mitochondrial dysfunction through ameliorating nicotinamide adenine dinucleotide biosynthesis, which inhibits the accelerated senescence of AT2 cells. Concurrently, pathological epithelial remodeling and fibroblast activation induced by impaired AT2 cells are terminated, ultimately prompting alveolar regeneration. Our data demonstrated that the mRNA-LNP system exhibited high protein expression in lung epithelial cells, which markedly extricated the alveolar collapse and prolonged the survival of fibrosis mice, providing a clinically viable strategy against IPF.

3 January 2023 in Materials & Design
Verified
Journal Article
Open access
SWSongqi Wang
Songqi Wang
YZYulin Zhang
Yulin Zhang
FSFengying Sun
Fengying Sun
KXKaiyan Xi
Kaiyan Xi
ZSZhenwei Sun
Zhenwei Sun
LSLei Sun
Lei Sun

29 August 2024 in Advanced Materials
Verified
Journal Article
Closed access
YZYulin Zhang
Yulin Zhang
ZFZezheng Fang
Zezheng Fang
ZLZejuan Liu
Zejuan Liu
KXKaiyan Xi
Kaiyan Xi
YZYi Zhang
Yi Zhang
SNShilei Ni
Shilei Ni

1 January 2024 in Theranostics
Verified
Journal Article
Open access
PDF file
FFFan Feng
Fan Feng
JSJianyu Shen
Jianyu Shen
QQQichao Qi
Qichao Qi
YZYulin Zhang
Yulin Zhang
SNShilei Ni
Shilei Ni
Brain tumors pose formidable challenges in oncology due to the intricate biology and the scarcity of effective treatment modalities. The emergence of immunotherapy has opened new avenues for innovative therapeutic strategies. Chimeric antigen receptor, originally investigated in T cell-based therapy, has now expanded to encompass macrophages, presenting a compelling avenue for augmenting anti-tumor immune surveillance. This emerging frontier holds promise for advancing the repertoire of therapeutic options against brain tumors, offering potential breakthroughs in combating the formidable malignancies of the central nervous system. Tumor-associated macrophages constitute a substantial portion, ranging from 30% to 50%, of the tumor tissue and exhibit tumor-promoting phenotypes within the immune-compromised microenvironment. Constructing CAR-macrophages can effectively repolarize M2-type macrophages towards an M1-type phenotype, thereby eliciting potent anti-tumor effects. CAR-macrophages can recruit T cells to the brain tumor site, thereby orchestrating a remodeling of the immune niche to effectively inhibit tumor growth. In this review, we explore the potential limitations as well as strategies for optimizing CAR-M therapy, offering insights into the future direction of this innovative therapeutic approach.